Premium
Dopamine‐1 Receptor Agonist: Renal Effects and Its Potential Role in the Management of Radiocontrast‐Induced Nephropathy
Author(s) -
Asif Arif,
Epstein David L.,
Epstein Murray
Publication year - 2004
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270004269842
Subject(s) - fenoldopam , medicine , nephropathy , renal blood flow , agonist , dopamine agonist , renal function , pharmacology , urology , endocrinology , receptor , diabetes mellitus
Radiocontrast‐induced nephropathy remains the third leading cause of hospital‐acquired acute renal failure. Once established, this syndrome is associated with increased morbidity and mortality as well as increased health care costs. Recently, studies have been initiated to evaluate the potential of a selective dopamine‐1 receptor agonist (fenoldopam) in ameliorating radiocontrast‐induced renal failure. Selective dopamine‐1 receptor agonists exhibit many desirable renal effects that support their use for the prophylaxis of radiocontrast‐induced nephropathy, including decreases in renal vascular resistance and increases in renal blood flow, glomerular filtration, and sodium and water excretion. Several reports have documented a beneficial effect of fenoldopam administration in attenuating radiocontrast‐induced nephropathy. In contrast, a recent multicenter, randomized study did not demonstrate a renoprotective effect of fenoldopam against radiocontrast‐induced nephropathy. The presence of multiple confounders, however, precludes a definitive conclusion regarding the ability of fenoldopam to protect against radiocontrast‐induced nephropathy. Additional studies are needed to properly evaluate the role of fenoldopam in radiocontrast‐induced nephropathy prophylaxis.